dr. grivas on comparisons between atm and brca1/2 mutations in mcrpc
Published 4 years ago • 1.3K plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
16:07
profound trial shows increased rpfs in mcrpc patients with brca1, brca2, and atm mutations
-
1:04
dr. grivas on potential combinations with cabazitaxel in prostate cancer
-
1:18
dr. gomella discusses role of brca1/2 in prostate cancer
-
1:42
ask dr. domchek: the differences between brca1 and brca2
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
1:17
dr. grivas on promising combination therapies in bladder cancer
-
1:35
dr. grivas on cabazitaxel/enzalutamide in mcrpc
-
3:57
germline atm vs brca2 mutations affecting therapy outcomes in prostate cancer
-
1:07
understanding prostate cancer mutations is critical
-
5:07
response to olaparib among men with brca 1 / 2 or atm mutated prostate cancer
-
0:49
how the breast cancer gene also impacts risk for prostate cancer
-
8:37
brca1 and brca2 mutations & cancer (types of cancer, and who’s most at risk)
-
12:07
parp inhibitors in brca1/2-mutated patients in prostate cancer
-
0:58
dr. litton on the embraca trial in advanced brca1/2 breast cancer
-
1:15
dr. churpek on gene mutations in breast cancer
-
0:19
copy of dr. grivas on promising combination therapies in bladder cancer
-
1:47
dr. grivas on combining chemotherapy and immunotherapy in bladder cancer
-
1:28
dr. giri on the progress registry for genetic testing in prostate cancer
-
9:02
chemotherapy for brca-mutated prostate cancer